FHD-286

Product Name: FHD-286
CAS No.: 2671128-05-3
Chemical Name: FHD-286
Synonyms: FHD-286;Inhibitor,inhibit,FHD 286,FHD-286,Epigenetic Reader Domain,FHD286;N-[(S)-1-[[4-[6-[(2R,6S)-2,6-Dimethylmorpholino]-2-pyridyl]-2-thiazolyl]amino]-3-methoxy-1-oxo-2-propyl]-1-(methylsulfonyl)-1H-pyrrole-3-carboxamide;N-[(1S)-2-[[4-[6-[cis-2,6-dimethylmorpholin-4-yl]-2-pyridyl]thiazol-2-yl]amino]-1-(methoxymethyl)-2-oxo-ethyl]-1-methylsulfonyl-pyrrole-3-carboxamide;N-[(2S)-1-[[4-[6-[(2S,6R)-2,6-dimethyl-4-morpholinyl]-2-pyridinyl]-2-thiazolyl]amino]-3-methoxy-1-oxopropan-2-yl]-1-methylsulfonyl-3-pyrrolecarboxamide;N-((S)-1-((4-(6-((2R,6S)-2,6-Dimethylmorpholino)pyridin-2-yl)thiazol-2-yl)amino)-3-methoxy-1-oxopropan-2-yl)-1-(methylsulfonyl)-1H-pyrrole-3-carboxamide;1H-Pyrrole-3-carboxamide, N-[(1S)-2-[[4-[6-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-pyridinyl]-2-thiazolyl]amino]-1-(methoxymethyl)-2-oxoethyl]-1-(methylsulfonyl)-
CBNumber: CB410298404
Molecular Formula: C24H30N6O6S2
Formula Weight: 562.66
MOL File: 2671128-05-3.mol

More

Less

FHD-286 Property

Density: 1.46±0.1 g/cm3(Predicted)
storage temp.: Store at -20°C
solubility: DMSO : 250 mg/mL (444.32 mM; Need ultrasonic)
pka: 7.18±0.50(Predicted)
form: Solid
color: Off-white to light yellow
InChI: InChI=1S/C24H30N6O6S2/c1-15-10-29(11-16(2)36-15)21-7-5-6-18(25-21)20-14-37-24(27-20)28-23(32)19(13-35-3)26-22(31)17-8-9-30(12-17)38(4,33)34/h5-9,12,14-16,19H,10-11,13H2,1-4H3,(H,26,31)(H,27,28,32)/t15-,16+,19-/m0/s1
InChIKey: JBLQNFBXKOAIHG-FCEWJHQRSA-N
SMILES: N1(S(C)(=O)=O)C=CC(C(N[C@@H](COC)C(NC2=NC(C3=NC(N4C[C@H](C)O[C@H](C)C4)=CC=C3)=CS2)=O)=O)=C1

More

Less

Hazard and Precautionary Statements (GHS)

More

Less

FHD-286 Chemical Properties,Usage,Production

Description

FHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 (SMARCA4) and BRM (SMARCA2), two highly similar proteins that are the ATPases, or the catalytic engines of the BAF complex, one of the critical regulators within the chromatin regulatory system. In preclinical studies, FHD-286 has shown anti-tumour activity across a broad range of malignancies, including hematologic and solid tumours. FHD-286 is being developed for relapsed and/or refractory AML.

FHD-286 Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

FHD-286 Suppliers

China 44 United States 4 Global 48

Shanghai XingMo Biotechnology Co., Ltd.

Tel: 13524779951
Fax: QQ: 2075692521
Email: 2075692521@qq.com
Country: China
ProdList: 310
Advantage: 55

Suzhou youruike Chemical Pharmaceutical Technology Co., Ltd

Tel: 15317229551
Fax: QQ:3607245178
Email: 15151849396@163.com
Country: China
ProdList: 1000
Advantage: 58

WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.

Tel: 17702719238 17702719238
Email: sales@sun-shinechem.com
Country: China
ProdList: 976
Advantage: 64

ShangHai Caerulum Pharma Discovery Co., Ltd.

Tel: 18149758185 18149758185
Email: sales-cpd@caerulumpharma.com
Country: China
ProdList: 3466
Advantage: 58

Shanghai Lollane Biological Technology Co.,Ltd.

Tel: 021-52996696，15000506266 15000506266
Fax: +86-21-52996696
Country: China
ProdList: 4512
Advantage: 55

Chengdu DingDang Pharmaceutical Co., Ltd.

Tel: 028-86040038 13980902949;
Fax: 028-85149890
Email: market@dingdangchem.com
Country: China
ProdList: 1843
Advantage: 55

Shanghai Chaolan Chemical Technology Center

Tel: QQ:65489617 15618227136
Fax: 21-5161 9052
Email: Sales@ATKchemical.com
Country: China
ProdList: 7257
Advantage: 58

Shanghai SuperLan Chemcial Technique Centre

Tel: 021-2022843681 15618226720
Fax: +86-21-51601218
Email: lucy@atkchemical.com
Country: China
ProdList: 8752
Advantage: 58

Shenzhen SUNGENING Bio-Medical Co., Ltd.

Tel: 0755-28967200 13631290199
Fax: 0755-28967200
Email: wxf@sungening.com
Country: China
ProdList: 9577
Advantage: 60

Jiaxing Deyi Chemical Co., Ltd.

Tel: 0573-86-0573-85866609 13325730825
Fax: 0573-85866609
Email: 945717149@qq.com
Country: China
ProdList: 8026
Advantage: 58

2671128-05-3, FHD-286Related Search:

1H-Pyrrole-3-carboxamide, N-[(1S)-2-[[4-[6-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-pyridinyl]-2-thiazolyl]amino]-1-(methoxymethyl)-2-oxoethyl]-1-(methylsulfonyl)-

FHD-286

Inhibitor,inhibit,FHD 286,FHD-286,Epigenetic Reader Domain,FHD286

N-[(1S)-2-[[4-[6-[cis-2,6-dimethylmorpholin-4-yl]-2-pyridyl]thiazol-2-yl]amino]-1-(methoxymethyl)-2-oxo-ethyl]-1-methylsulfonyl-pyrrole-3-carboxamide

N-[(S)-1-[[4-[6-[(2R,6S)-2,6-Dimethylmorpholino]-2-pyridyl]-2-thiazolyl]amino]-3-methoxy-1-oxo-2-propyl]-1-(methylsulfonyl)-1H-pyrrole-3-carboxamide

N-[(2S)-1-[[4-[6-[(2S,6R)-2,6-dimethyl-4-morpholinyl]-2-pyridinyl]-2-thiazolyl]amino]-3-methoxy-1-oxopropan-2-yl]-1-methylsulfonyl-3-pyrrolecarboxamide

N-((S)-1-((4-(6-((2R,6S)-2,6-Dimethylmorpholino)pyridin-2-yl)thiazol-2-yl)amino)-3-methoxy-1-oxopropan-2-yl)-1-(methylsulfonyl)-1H-pyrrole-3-carboxamide

2671128-05-3

671128-05-3

C24H30N6O6S2